BIO compared with NE: revenue, margins and what each company keeps, and the suppliers and customers both name

BIOBio-Rad Laboratories, Inc.

Mkt capRevenueRevenue

NENoble Corp plc

Mkt capRevenueRevenue

Compare

BIOBio-Rad Laboratories, Inc.

NENoble Corp plc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

BIO1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+4.50%—

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±9.4%▼−5.42%×0.57

Q2 FY26±7.6%▼−9.07%×1.20

= impliedBIO realized, solidNE realized, hatchedOne scale, both sides: full bar = 10%× = |realized| ÷ impliedSource: market data

Q1 FY26

±7.9%

▲+8.20%

×1.04

Feb 12 '26±7.6%▼−3.36%×0.45

BIOBio-Rad Laboratories, Inc.

362.51▼−2.60%· post 362.52

Mkt cap$10.0BRevenue$651MQ2 FY26Revenue$2.6BFY25

NENoble Corp plc

45.43▼−7.29%· post 45.60

ClosedNov 2 '26

Mkt cap$7.8BRevenue$729MQ3 FY26Revenue$3.3BFY25

Compare

ClosedNov 2 '26

BIOBio-Rad Laboratories, Inc.

NENoble Corp plc

362.51▼−2.60%post 362.52

Price

45.43▼−7.29%post 45.60

$10.0B

Mkt cap

$7.8B

Q2 FY26$651M

Revenue

$729MQ3 FY26

FY25$2.6B

Revenue

$3.3BFY25

BIO362.51▼−2.60%vsNE45.43▼−7.29%ClosedNov 2 '26